-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 -- -- Received remaining $25 million investment under previously announced private placement financing -- ARLINGTON, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback